Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 19: 1255-1258, 1973;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berry, A. J.
Right arrow Articles by Grannis, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, A. J.
Right arrow Articles by Grannis, G. F.

Clinical Chemistry, Vol 19, 1255-1258, Copyright © 1973 by the American Association for Clinical Chemistry

NADH Preparations as They Affect Reliability of Serum Lactate Dehydrogenase Determinations

Arnold J. Berry 1, John A. Lott 1, and George F. Grannis 1

1 Division of Clinical Chemistry, Department of Pathology, Ohio State University. 410 W. 10th Ave., Columbus, Ohio 43210.

We observed large variations in the activity of lactate dehydrogenase (EC 1.1.1.27) in serum when random lots of NADH were used in its determination. The imprecision, caused by variable amounts of lactate dehydrogenase inhibitor in the NADH preparations, was greatly lessened by using only a single lot of NADH; reliability was improved further by selecting an NADH preparation having a negligible amount of inhibitor. A method is described for assessing the quality of commercial NADH preparations, so as to have a satisfactory reagent and to maintain continuously comparable results over an extended period of time. The results have possible relevance for proposed governmental regulation of commercial kits and reagents used for clinical laboratory testing, and for improved intraand inter-laboratory comparability of lactate dehydrogenase determinations.


Key Words: LD inhibitor • NADH impurity • quality control • regulation of kits and reagents • performance improvement • normal range • commercial kits

Submitted on June 28, 1973






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1973 by the American Association for Clinical Chemistry.